Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) recorded Income from Non-Controlling Interests of -$6,478 in the quarter ended Jun 30, 2026, compared with -$6,767 a year earlier.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
On a TTM basis, Eupraxia Pharmaceuticals' Income from Non-Controlling Interests came in at -$25,968 as of Jun 30, 2026; for the year ended Dec 31, 2025, it came in at -$29,509.
- Across earlier years, Income from Non-Controlling Interests came in at -$241,953 in the year ended Dec 31, 2024, -$745,210 in the year ended Dec 31, 2023 and -$501,135 in the year ended Dec 31, 2022.
- Quarterly Income from Non-Controlling Interests has ranged from -$380,394 in the quarter ended Dec 31, 2023 to -$1,415 in the quarter ended Mar 31, 2026 over the past five years.
- Per Business Quant, the preceding three quarters came in at -$1,415 (quarter ended Mar 31, 2026), -$10,084 (quarter ended Dec 31, 2025) and -$7,991 (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | - |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | - |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Eupraxia Pharmaceuticals | 289.28 Mn | 287.68 Mn | - | -6,478.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,478.00 |
| Mar 31, 2026 | -1,415.00 |
| Dec 31, 2025 | -10,084.00 |
| Sep 30, 2025 | -7,991.00 |
| Jun 30, 2025 | -6,767.00 |
| Mar 31, 2025 | -4,667.00 |
| Dec 31, 2024 | -23,385.00 |
| Sep 30, 2024 | -47,995.00 |
| Jun 30, 2024 | -56,678.00 |
| Mar 31, 2024 | -113,895.00 |
| Dec 31, 2023 | -380,394.00 |
| Sep 30, 2023 | -174,741.00 |
| Jun 30, 2023 | -129,379.00 |
| Mar 31, 2023 | -60,696.00 |
API Access
Eupraxia Pharmaceuticals Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();